Total Payments
$605,734
2024 Payments
$88,687
Companies
38
Transactions
562
Medicare Patients
935
Medicare Billing
$380,957
Payment Breakdown by Category
Other$379,737 (62.7%)
Consulting$125,168 (20.7%)
Travel$82,773 (13.7%)
Food & Beverage$16,388 (2.7%)
Research$1,607 (0.3%)
Education$62.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $363,228 | 105 | 60.0% |
| Consulting Fee | $125,168 | 47 | 20.7% |
| Travel and Lodging | $82,773 | 187 | 13.7% |
| Honoraria | $16,509 | 6 | 2.7% |
| Food and Beverage | $16,388 | 210 | 2.7% |
| Unspecified | $1,607 | 1 | 0.3% |
| Education | $62.00 | 6 | 0.0% |
Payments by Type
General
$604,127
561 transactions
Research
$1,607
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| BeiGene USA, Inc. | $165,117 | 123 | $0 (2024) |
| Incyte Corporation | $98,723 | 80 | $0 (2024) |
| Astellas Pharma US Inc | $85,986 | 74 | $0 (2024) |
| Rigel Pharmaceuticals, Inc. | $62,604 | 47 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $40,461 | 46 | $0 (2020) |
| Celgene Corporation | $35,663 | 26 | $0 (2018) |
| Teva Pharmaceuticals USA, Inc. | $25,752 | 24 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $16,403 | 28 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $12,223 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $11,123 | 17 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $88,687 | 75 | BeiGene USA, Inc. ($37,118) |
| 2023 | $89,796 | 74 | BeiGene USA, Inc. ($56,128) |
| 2022 | $77,711 | 60 | BeiGene USA, Inc. ($32,183) |
| 2021 | $49,952 | 40 | BeiGene USA, Inc. ($35,168) |
| 2020 | $32,518 | 25 | Incyte Corporation ($14,759) |
| 2019 | $124,139 | 135 | Astellas Pharma US Inc ($48,072) |
| 2018 | $54,543 | 75 | Pharmacyclics LLC, An AbbVie Company ($18,594) |
| 2017 | $88,390 | 78 | Celgene Corporation ($31,572) |
All Payment Transactions
562 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $52.20 | General |
| Category: CELLT | ||||||
| 12/06/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $30.86 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $204.56 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $193.30 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 11/07/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $23.99 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/22/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $141.33 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/17/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,744.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 10/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,500.00 | General |
| Category: Oncology | ||||||
| 10/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $809.93 | General |
| Category: Oncology | ||||||
| 10/09/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $108.05 | General |
| Category: Oncology | ||||||
| 10/06/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 10/03/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,148.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 09/21/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Travel and Lodging | Cash or cash equivalent | $452.95 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 09/04/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | Cash or cash equivalent | $186.85 | General |
| Category: Oncology | ||||||
| 08/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,000.00 | General |
| Category: Oncology | ||||||
| 08/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $462.71 | General |
| Category: Oncology | ||||||
| 08/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $287.95 | General |
| Category: Oncology | ||||||
| 08/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Travel and Lodging | In-kind items and services | $264.35 | General |
| Category: Oncology | ||||||
| 08/23/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $133.50 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Honoraria | Cash or cash equivalent | $1,463.00 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 06/18/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| Category: Oncology | ||||||
| 06/08/2024 | Astellas Pharma US Inc | Xospata (Drug) | Consulting Fee | Cash or cash equivalent | $6,230.00 | General |
| Category: Oncology | ||||||
| 06/08/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $75.80 | General |
| Category: Oncology | ||||||
| 06/08/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $62.39 | General |
| Category: Oncology | ||||||
| 06/08/2024 | Astellas Pharma US Inc | Xospata (Drug) | Food and Beverage | In-kind items and services | $50.80 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 OPEN-LABEL RANDOMIZED STUDY OF PIRTOBRUTINIB (LOXO-305) VERSUS IBRUTINIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN-CLL-314) | Eli Lilly and Company | $1,607 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 276 | 1,179 | $501,337 | $134,917 |
| 2022 | 7 | 242 | 979 | $407,141 | $101,084 |
| 2021 | 6 | 257 | 1,072 | $453,781 | $116,276 |
| 2020 | 4 | 160 | 503 | $116,209 | $28,680 |
Total Patients
935
Total Services
3,733
Medicare Billing
$380,957
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 75 | 607 | $240,979 | $66,841 | 27.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 88 | 448 | $188,584 | $51,860 | 27.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 34 | 37 | $28,712 | $5,830 | 20.3% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 33 | 40 | $16,360 | $4,306 | 26.3% |
| 38221 | Biopsy of bone marrow | Office | 2023 | 15 | 16 | $9,984 | $2,502 | 25.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $9,630 | $2,306 | 23.9% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 16 | 16 | $7,088 | $1,272 | 18.0% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 68 | 536 | $212,792 | $50,475 | 23.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 76 | 321 | $135,141 | $36,714 | 27.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 30 | 36 | $27,936 | $6,353 | 22.7% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 27 | 37 | $15,133 | $3,668 | 24.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 11 | 11 | $7,062 | $1,802 | 25.5% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 16 | 16 | $7,097 | $1,574 | 22.2% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2022 | 14 | 22 | $1,980 | $498.90 | 25.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 76 | 611 | $242,567 | $59,860 | 24.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 80 | 331 | $139,351 | $39,574 | 28.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 37 | 51 | $39,576 | $9,102 | 23.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2021 | 39 | 49 | $19,981 | $4,700 | 23.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 11 | 11 | $7,062 | $1,811 | 25.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 19 | $5,244 | $1,229 | 23.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 70 | 204 | $81,781 | $20,031 | 24.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 62 | $17,112 | $4,259 | 24.9% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 18 | 106 | $16,006 | $4,000 | 25.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2020 | 55 | 131 | $1,310 | $390.00 | 29.8% |
About Delong Liu, M.D., PH.D
Delong Liu, M.D., PH.D is a Hematology healthcare provider based in Hawthorne, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/08/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538122932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Delong Liu, M.D., PH.D has received a total of $605,734 in payments from pharmaceutical and medical device companies, with $88,687 received in 2024. These payments were reported across 562 transactions from 38 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($363,228).
As a Medicare-enrolled provider, Liu has provided services to 935 Medicare beneficiaries, totaling 3,733 services with total Medicare billing of $380,957. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Hawthorne, NY
- Active Since 04/08/2006
- Last Updated 07/16/2019
- Taxonomy Code 207RH0000X
- Entity Type Individual
- NPI Number 1538122932
Products in Payments
- BRUKINSA (Drug) $158,385
- JAKAFI (Drug) $87,047
- XOSPATA (Drug) $45,522
- Rezlidhia (Drug) $41,340
- Imbruvica (Drug) $40,461
- Revlimid (Drug) $35,554
- Xospata (Drug) $33,757
- BENDEKA (Drug) $25,752
- Tavalisse (Drug) $21,264
- CALQUENCE (Drug) $14,534
- ICLUSIG (Drug) $12,125
- BESREMI (Drug) $9,517
- VYXEOS (Drug) $9,384
- IMBRUVICA (Drug) $8,176
- SCEMBLIX (Drug) $7,425
- SARCLISA (Biological) $7,295
- EMPLICITI (Biological) $4,185
- DARZALEX (Biological) $2,925
- BLENREP (Biological) $2,600
- MYLOTARG (Biological) $2,400
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.